bioAffinity Technologies Receives Nasdaq Delisting Notice
bioAffinity Technologies, Inc. received a notice from Nasdaq on July 30, 2026, indicating non-compliance with the minimum bid price requirement, as its shares traded below $1.00 for 30 consecutive business days. The company is not eligible for the standard 180-day compliance period due to a 1-for-30 reverse stock split effected on September 19, 2025. bioAffinity Technologies plans to appeal the determination to Nasdaq on August 6, 2026, which will temporarily halt the delisting process.
Key Highlights
- Received Nasdaq delisting notice on July 30, 2026, for non-compliance.
- Bid price closed below $1.00 per share for 30 consecutive business days.
- Not eligible for 180-day compliance period due to prior reverse stock split.
- Effected a 1-for-30 reverse stock split on September 19, 2025.
- Company intends to appeal to Nasdaq on August 6, 2026.
- Appeal will stay delisting and suspension of securities pending Panel decision.
Price Impact
More from BIAF
bioAffinity Technologies Calls Special Meeting for Warrant, Share Authorization Votes
bioAffinity Technologies Reports Q2 Net Loss of $3.37M; Going Concern Doubt
bioAffinity Q2 Revenue $1.5M, Net Loss $3.4M; CyPath Lung Volume +216%